All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mitazalimab
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2020
Details:
The upcoming Phase II study OPTIMIZE-1 is an open-label, multicenter study evaluating the clinical effect of mitazalimab in combination with chemotherapy (mFolfirinox) in patients with advanced pancreatic cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mitazalimab
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2020
Details:
Recently, new benchmark data was published showing that mitazalimab has the potential to be best-in-class in the CD40 field. The comparison demonstrated the potent immune-activating properties and anti-tumor effects of mitazalimab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATOR-1015
Therapeutic Area: Oncology Product Name: ATOR-1015
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The presentations include the phase I study with ATOR-1015, the project ALG-APV-527 which is being developed in collaboration with Aptevo Therapeutics and is ready for clinical phase I studies, and the new bispecific concept Neo-X-Prime.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATOR-1017
Therapeutic Area: Oncology Product Name: ATOR-1017
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
The Data Review Committee, which monitors the safety of patients in the Phase I study with ATOR-1017, has approved the dose of 100 mg and granted the start of dosing with 200 mg, corresponding to approximately 3.2 mg / kg.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATOR-1017,Mitazalimab
Therapeutic Area: Oncology Product Name: ATOR-1017
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
Positive safety data and Proof of Mechanism data form the basis for the decision to continue two projects in clinical efficacy studies (phase Ib / II) in 2021 evaluating ATOR-1017 and mitazalimab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mitazalimab
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2020
Details:
The results from the study show that a large number of genes are upregulated after treatment with mitazalimab, for example PD-L1, which supports the clinical development plan for mitazalimab which includes combination studies with PD-1 inhibitors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATOR-1017
Therapeutic Area: Oncology Product Name: ATOR-1017
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
The Data Review Committee that monitors the safety of the patients in the ATOR-1017 Phase I study, has cleared the 40 mg dose and approved to start dosing with the higher dose level of 100 mg, corresponding to approximately 1.6 mg/kg.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mitazalimab
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
Alligator plans to submit a CTA, to start a Phase II clinical study. The study (OPTIMIZE-1) is an open multicenter study to evaluate the clinical effect of mitazalimab in combination with chemotherapy (mFolfirinox) in patients with spread of pancreatic cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATOR-1015
Therapeutic Area: Oncology Product Name: ATOR-1015
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Details:
Interim data from up to 21 cancer patients was presented at the oncology conferences AACR and ASCO, showing a promising safety and tolerability for ATOR-1015. Currently, patients are given doses of 750 mg, approximately 12.5 mg/kg, every two weeks.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATOR-1017
Therapeutic Area: Oncology Product Name: ATOR-1017
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
Details:
US Patent Office (USPTO) has issued an approved patent for the drug candidate ATOR-1017, Alligator's wholly owned 4-1BB antibody in clinical development phase I for the treatment of disseminated cancer.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
